We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current RNA market cap is 4.79B. The company's latest EPS is USD -1.7951 and P/E is -22.58.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 2.32M | 2.82M | 2.19M | 3.54M | 2.05M |
| Operating Income | -52.63M | -58.63M | -66.74M | -77.19M | -82.63M |
| Net Income | -47.03M | -52.36M | -60.44M | -68.86M | -70.79M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 2.32M | 6.79M | 9.33M | 9.22M | 9.56M |
| Operating Income | -17.33M | -44.28M | -118.05M | -178.91M | -235.6M |
| Net Income | -24.73M | -44.36M | -118.01M | -174M | -212.22M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 610.78M | 573.16M | 628.56M | 951.47M | 1.35B |
| Total Liabilities | 51.61M | 55.7M | 127.79M | 120.58M | 126.39M |
| Total Equity | 559.18M | 517.47M | 500.76M | 830.9M | 1.22B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 96.91M | 333.9M | 427.58M | 638.8M | 628.56M |
| Total Liabilities | 27.54M | 27.68M | 46.15M | 60.73M | 127.79M |
| Total Equity | -65.36M | 306.22M | 381.43M | 578.08M | 500.76M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -98.77M | -135.57M | -119.06M | -70.38M | -135.38M |
| Investing | -149.63M | -181.11M | -130.07M | -32.75M | -307.62M |
| Financing | 61.93M | 61.97M | 93.86M | 389.45M | 836.17M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 2.49M | -37.12M | -94.81M | -136.27M | -119.06M |
| Investing | -235k | -7.79M | -82.52M | -189.96M | -130.07M |
| Financing | 89.23M | 272.04M | 176.32M | 346.17M | 93.86M |
| Market Cap | 4.79B |
| Price to Earnings Ratio | -22.58 |
| Price to Sales Ratio | 501.11 |
| Price to Cash Ratio | 25.89 |
| Price to Book Ratio | 9.57 |
| Dividend Yield | - |
| Shares Outstanding | 118.22M |
| Average Volume (1 week) | 1.27M |
| Average Volume (1 Month) | 1.31M |
| 52 Week Change | 78.75% |
| 52 Week High | 48.8012 |
| 52 Week Low | 4.825 |
| Spread (Intraday) | 32.58 (66.76%) |
| Company Name | Avidity Biosciences Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.aviditybiosciences.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
